SFDA To Prioritize Raising Standards For Essential Drugs
This article was originally published in PharmAsia News
China's State FDA will soon release regulations on tightening the monitoring and supervision of the quality of essential drugs, with a focus on raising standards for these items. SFDA officials point out that the implementation of a new national essential drugs system will boost the usage of drugs on the list, thus any slip-up could have serious consequences. The agency demands that local drug administrations should strictly enforce provisions of the upcoming regulations; fully understand the types of essential drugs when the list is released, as well as their status, supervisory objectives and measures; enhance monitoring along the entire pathway of drug R&D, production, distribution and application; and raise the level of scientific management. (Click here for more - Chinese Language)
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.